Dataset Information

Guidelines for Biosafety in Teaching Laboratories Version 2.0: A Revised and Updated Manual for 2019.

ABSTRACT: The original Guidelines for Biosafety in Teaching Laboratories were developed in 2012 in response to an outbreak of Salmonella Typhimurium tracked by the Centers for Disease Control and Prevention (CDC) that originated from clinical and teaching microbiology laboratories. In the 7 years since the publication of the guidelines, there have been two subsequent CDC-reported Salmonella outbreaks originating from clinical and teaching microbiology laboratories. Use of and issues with the guidelines by ASM members have been tracked by various means since publication, and in 2018 it became apparent that an update of the guidelines was necessary. The Education Board of the American Society for Microbiology charged this task force with updating the guidelines based on the accumulated information. While the guidelines should look familiar, users will find that the originally separate BSL1 and BSL2 guidelines have been rolled into one document, to help eliminate redundancy and confusion. In addition, sections on risk assessment and service animals in the teaching laboratory have been added. These updated guidelines should help clarify many of the issues for which users expressed problems with the original guidelines.

SUBMITTER: Byrd JJ

PROVIDER: S-EPMC6914345 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Guidelines for Biosafety in Teaching Laboratories Version 2.0: A Revised and Updated Manual for 2019.

Byrd Jeffrey J JJ Emmert Elizabeth E Maxwell Robert R Townsend Heather H

Journal of microbiology & biology education 20191218 3

The original <i>Guidelines for Biosafety in Teaching Laboratories</i> were developed in 2012 in response to an outbreak of Salmonella Typhimurium tracked by the Centers for Disease Control and Prevention (CDC) that originated from clinical and teaching microbiology laboratories. In the 7 years since the publication of the guidelines, there have been two subsequent CDC-reported <i>Salmonella</i> outbreaks originating from clinical and teaching microbiology laboratories. Use of and issues with the ...[more]

PMID: 31890075

Similar Datasets

Project description:Li-Fraumeni syndrome (LFS) is a hereditary tumor that exhibits autosomal dominant inheritance. LFS develops in individuals with a pathogenic germline variant of the cancer-suppressor gene, TP53 (individuals with TP53 pathogenic variant). The number of individuals with TP53 pathogenic variant among the general population is said to be 1 in 500 to 20,000. Meanwhile, it is found in 1.6% (median value, range of 0-6.7%) of patients with pediatric cancer and 0.2% of adult patients with cancer. LFS is diagnosed by the presence of germline TP53 pathogenic variants. However, patients can still be diagnosed with LFS even in the absence of a TP53 pathogenic variant if the familial history of cancers fit the classic LFS diagnostic criteria. It is recommended that TP53 genetic testing be promptly performed if LFS is suspected. Chompret criteria are widely used for the TP53 genetic test. However, as there are a certain number of cases of LFS that do not fit the criteria, if LFS is suspected, TP53 genetic testing should be performed regardless of the criteria. The probability of individuals with TP53 pathogenic variant developing cancer in their lifetime (penetrance) is 75% for men and almost 100% for women. The LFS core tumors (breast cancer, osteosarcoma, soft tissue sarcoma, brain tumor, and adrenocortical cancer) constitute the majority of cases; however, various types of cancers, such as hematological malignancy, epithelial cancer, and pediatric cancers, such as neuroblastoma, can also develop. Furthermore, approximately half of the cases develop simultaneous or metachronous multiple cancers. The types of TP53 pathogenic variants and factors that modify the functions of TP53 have an impact on the clinical presentation, although there are currently no definitive findings. There is currently no cancer preventive agent for individuals with TP53 pathogenic variant. Surgical treatments, such as risk-reducing bilateral mastectomy warrant further investigation. Theoretically, exposure to radiation could induce the onset of secondary cancer; therefore, imaging and treatments that use radiation should be avoided as much as possible. As a method to follow-up LFS, routine cancer surveillance comprising whole-body MRI scan, brain MRI scan, breast MRI scan, and abdominal ultrasonography (US) should be performed immediately after the diagnosis. However, the effectiveness of this surveillance is unknown, and there are problems, such as adverse events associated with a high rate of false positives, overdiagnosis, and sedation used during imaging as well as negative psychological impact. The detection rate of cancer through cancer surveillance is extremely high. Many cases are detected at an early stage, and treatments are low intensity; thus, cancer surveillance could contribute to an improvement in QOL, or at least, a reduction in complications associated with treatment. With the widespread use of genomic medicine, the diagnosis of LFS is unavoidable, and a comprehensive medical care system for LFS is necessary. Therefore, clinical trials that verify the feasibility and effectiveness of the program, comprising LFS registry, genetic counseling, and cancer surveillance, need to be prepared.

Dataset Information

Guidelines for Biosafety in Teaching Laboratories Version 2.0: A Revised and Updated Manual for 2019.

Publications

Guidelines for Biosafety in Teaching Laboratories Version 2.0: A Revised and Updated Manual for 2019.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure